Opthea's Annual General Meeting Details
Opthea Limited (NASDAQ: OPT, ASX: OPT.AX) is pleased to announce the details for its upcoming Annual General Meeting (AGM). As a company dedicated to developing innovative treatments for retinal diseases, this meeting represents a pivotal moment for shareholders and stakeholders alike.
Significant Leadership Changes
Dr. Megan Baldwin, the Executive Director and a founding member of Opthea, will retire from the Board at the close of the AGM. This decision comes in alignment with the ASX Listing Rules and reflects Dr. Baldwin's commitment to prioritize her role as Chief Innovation Officer, focusing on advancing Opthea's groundbreaking innovation agenda.
Continuing Contributions
Dr. Baldwin has expressed her eagerness to lead the charge in pursuing new therapeutic approaches in ophthalmology. She remarks, "I am incredibly proud that our lead product, sozinibercept, has the potential to be a breakthrough treatment for wet age-related macular degeneration, a goal I've passionately pursued throughout my career.”
Board Appreciation
The Opthea Board of Directors, led by Chairman Jeremy Levin, has acknowledged Dr. Baldwin's invaluable contributions during her tenure. Mr. Levin stated, "Her insights and leadership have been pivotal in guiding Opthea through critical stages, especially as we prepare for the anticipated Phase 3 clinical data readouts for sozinibercept set for 2025.”
New Board Member Search
As part of the transition following Dr. Baldwin's retirement, Opthea is actively seeking a new Board member to fill the resulting vacancy. This addition to the Board is critical as the company navigates through significant developments in its clinical trials and aims to enhance its governance and strategic direction.
About Opthea Limited
Opthea Limited specializes in the development of innovative therapies aimed at treating severe and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead candidate, sozinibercept, is currently undergoing evaluation in critical Phase 3 trials. These studies focus on determining its effectiveness in combination with established therapies to improve patient outcomes significantly.
Sozinibercept Trials
The ongoing trials, COAST and ShORe, are fully enrolled and are a testament to the promising nature of sozinibercept in offering improved vision outcomes compared to traditional therapies. As Opthea continues in this quest, it's clear that the future holds hope for many patients seeking effective therapies for retinal diseases.
Investor and Media Relations
For those interested in keeping up with Opthea's advances, the company encourages inquiries. PJ Kelleher from LifeSci Advisors can be contacted for media and investor relations at pjkelleher@lifesciadvisors.com or via phone at 617-430-7579.
Frequently Asked Questions
What is the purpose of the Annual General Meeting?
The AGM allows shareholders to get updates on the company's performance and strategies, as well as to vote on important matters, including Board member appointments.
Who is retiring from the Opthea Board?
Dr. Megan Baldwin will retire from the Opthea Board of Directors during the AGM. She will continue her work as Chief Innovation Officer.
What does sozinibercept aim to treat?
Sozinibercept is being developed to treat retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema.
How can investors reach out to Opthea?
Investors can contact PJ Kelleher at LifeSci Advisors via email at pjkelleher@lifesciadvisors.com.
What is the timeline for the clinical trials?
The Phase 3 data readouts for sozinibercept are anticipated in 2025, marking significant progress in the company’s research endeavors.
